Magle Chemoswed aktie (MAGLE) | Pressmeddelande - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Erbjudande: Krypto visar motståndskraft – här kan du just nu handla kryptovalutor avgiftsfritt (annons)

Pressmeddelanden från Magle Chemoswed

 Bevaka pressreleaser
Kurs från TradingView
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

Malmö, Sweden – Magle Group announces a revised publication date for its 2024 Annual Report, and its Q1 2025 Interim Report.

Magle Group today announces a further postponement of the publication of its annual accounts for the financial year 2024.

MFN • 27 Apr 18:30

Correction: Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2024

This is a correction of the press release published on 27 March 2025 at 08:30 CET, titled “Magle Chemoswed Holding Reports Financial Results...

MFN • 25 Apr 16:30

Magle PharmaCept Partners with Pancreatic Cancer Europe PCE to Advance Innovation in Pancreatic Cancer Care

Magle PharmaCept, a part of Magle Group, announces a strategic partnership with Pancreatic Cancer Europe (PCE), Pancreatic Cancer Europe is ...

MFN • 25 Apr 09:00

Magle Group Announces Acquisition of Saving Chlora AB

Magle Chemoswed Holding AB ("Magle Group" or the "Company") has today, on 24 April 2025, signed a share purchase agreement regarding the acq...

MFN • 24 Apr 11:15

Kallelse till årsstämma i Magle Chemoswed Holding AB (publ)

Aktieägarna i Magle Chemoswed Holding AB (publ), org.

MFN • 24 Apr 09:00

Magle Group till BioStock: We live by the mantra ‘earn it before you burn it’

Igår publicerade Magle Group sin Q4-rapport som speglar ökade intäkter, underbyggd av organisk tillväxt och integrationen av två nyckelförvä...

Cision • 28 Mar 14:35

Magle Group to BioStock: We live by the mantra ‘earn it before you burn it’

Yesterday, Magle Group released their Q4 report showing a notable increase in revenue, underpinned by organic growth as well as the integrat...

Cision • 28 Mar 14:35

Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2024

Magle Group's Q4 report highlights strong organic growth in DSM and CDMO, integrates key acquisitions, and expands into dextran-based biopol...

MFN • 27 Mar 08:30

BioStock: Magle Group launches multicenter trial with pancreatic leakage indicator

Magle Group has partnered with Heidelberg University Hospital in Germany to launch a study evaluating the effectiveness of SmartPAN in pancr...

Cision • 24 Mar 12:35

Magle Group initiates Randomized Controlled Multicenter Trial with leading European university hospitals to explore SmartPAN® efficacy

Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the company has established a collaboration with Heidel...

MFN • 19 Mar 08:15

Ingela Fritzson resigns from the Board of Directors of Magle Group

Ingela Fritzson has today informed Magle Chemoswed Holding AB that she resigns from her position as employee representative in Magle Group’s...

MFN • 26 Feb 18:00

Magle Group is pleased to announce Magle PharmaCept’s participation in the DPC, German Pancreatic Club congress, set to take place February 27-March 1, 2025, in Heidelberg, Germany.

Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) is pleased to announce Magle PharmaCept’s participation in the DPC, German P...

MFN • 17 Feb 09:00

Magle Group Announces Revised Publication Date for Q4 2024 and Full-Year 2024 Reports Due to Ongoing Consolidation Process

Malmö, Sweden – Magle Group announces a revised publication date for its Q4 2024 and Full-Year 2024 financial report, and its 2024 Annual Re...

MFN • 14 Feb 08:05

Magle Group offentliggör tilldelning i den riktade emissionen

Den 12 december 2024 offentliggjorde Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") att Bolagets styrelse beslutat, villkorat av...

MFN • 09 Jan 21:45

Kommuniké från extra bolagsstämma i Magle Chemoswed Holding AB

Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") har idag hållit extra bolagsstämma.

MFN • 30 Dec 2024 12:30

Magle Group tillförs cirka 36,8 MSEK i företrädesemissionen

Styrelsen i Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") offentliggör idag, den 20 december 2024, utfallet i den företrädesemi...

MFN • 20 Dec 2024 15:30

Magle Group offentliggör tilläggsprospekt

Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") offentliggör idag tilläggsprospekt (”Tilläggsprospektet”) avseende det prospekt s...

MFN • 16 Dec 2024 15:30

Magle Group Approves Multi-Centre Clinical Trial in Genicular Artery Embolisation for Osteoarthritis Pain Relief

Magle Group is proud to announce that its approved the initiation of a multi-centre clinical trial to explore the use of EmboCept® S in Geni...

MFN • 16 Dec 2024 10:40

Kallelse till extra bolagsstämma i Magle Chemoswed Holding AB (publ)

Aktieägarna i Magle Chemoswed Holding AB (publ), org.

MFN • 12 Dec 2024 22:45

Magle Group beslutar om en villkorad riktad nyemission om upp till cirka 26,6 MSEK

Styrelsen i Magle Chemoswed Holding AB (publ) ("Magle Group" eller "Bolaget") har beslutat att genomföra en riktad nyemission av högst 887 3...

MFN • 12 Dec 2024 22:00

Magle Group offentliggör tilläggsprospekt

Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") offentliggör idag tilläggsprospekt (”Tilläggsprospektet”) avseende det prospekt s...

MFN • 10 Dec 2024 18:00

Appointment of Aaron Wong as CFO of Magle Group

Magle Group is pleased to announce the appointment of Aaron Wong as its new Chief Financial Officer (CFO), effective 7th January 2025.

MFN • 05 Dec 2024 08:50

Announcement of CFO Petra Jönsson Sjölin’s Resignation

Magle Group announces that Petra Jönsson Sjölin has decided to step down from her position as Chief Financial Officer (CFO).

MFN • 05 Dec 2024 08:50

Correction: Nomination Committee appointed for the annual general meeting 2025 in Magle Chemoswed Holding

In the previous press release that was made public on 3 December 2024 it was wrongly stated that Hans Henrik Lidgard is chair of the Nominat...

MFN • 04 Dec 2024 13:00

Nomination Committee appointed for the Annual General Meeting 2025 in Magle Chemoswed Holding

Malmö, Sweden – Magle Chemoswed Holding (publ) today announced the composition of the Nomination Committee for the Annual General Meeting 20...

MFN • 03 Dec 2024 11:30

Magle Group offentliggör prospekt avseende företrädesemissionen

Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") meddelar att prospektet avseende Bolagets företrädesemission av aktier (”Företräd...

MFN • 02 Dec 2024 17:30

Magle Group beslutar om företrädesemission om cirka 36,8 MSEK

Styrelsen i Magle Chemoswed Holding AB (”Magle Group” eller ”Bolaget”) har idag, den 22 november 2024, med stöd av bemyndigandet från årsstä...

MFN • 22 Nov 2024 08:30

Magle Chemoswed Holding Reports Financial Results For Third Quarter 2024

Magle Group (publ) reports strong Q3 2024 performance, with sales growth and strategic mergers positioning the company for future market exp...

MFN • 24 Oct 2024 08:30

Fusionen mellan Magle Group och Amniotics är slutförd

Bolagsverket har idag registrerat fusionen mellan Magle Chemoswed Holding AB ("Magle Group") och Amniotics AB (publ) ("Amniotics") ("Fusione...

MFN • 07 Oct 2024 11:45

Kvittningsemissionen till PRS1 ApS är genomförd

Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") offentliggjorde den 28 juni 2024 att Bolaget ingått ett samgåendeavtal med PRS1 A...

MFN • 04 Oct 2024 16:00

Kommuniké från extra bolagsstämma i Magle Chemoswed Holding AB

Magle Chemoswed Holding AB ("Magle Group") har idag hållit extra bolagsstämma.

MFN • 04 Oct 2024 11:00

Magle Group beslutar om emission av vederlagsaktier

Styrelsen för Magle Chemoswed Holding AB ("Magle Group") har idag, med stöd av bemyndigandet från årsstämman den 25 april 2024, beslutat att...

MFN • 04 Oct 2024 09:00

Magle Chemoswed and I2Pure Announce Joint Venture in Wound Care

In an ambitious move to transform wound care, Magle Chemoswed and I2Pure have unveiled a joint venture, marrying I2Pure's groundbreaking mol...

MFN • 02 Oct 2024 09:00

Bolagsverket har lämnat tillstånd att verkställa fusionsplanen mellan Magle Group och Amniotics

Bolagsverket har idag lämnat tillstånd till Magle Chemoswed Holding AB ("Magle Group") att verkställa fusionsplanen avseende fusionen mellan...

MFN • 23 Sep 2024 13:30

Kallelse till extra bolagsstämma i Magle Chemoswed Holding AB (publ)

Aktieägarna i Magle Chemoswed Holding AB (publ), org.

MFN • 18 Sep 2024 09:15

BioStock: How Magle Group focus their use of DSM

The company aims to establish itself as a leader in life-changing healthcare innovations.

Cision • 21 Aug 2024 09:30

BioStock: Magle Group ger en halvårsöversikt och blickar framåt

BioStock intervjuar Magle Group om bolagets rapport för det första halvåret 2024 och dyker in bland annat in i bolagets tillväxt, den ökade ...

Cision • 18 Jul 2024 14:58

Magle Chemoswed Holding Reports Financial Results For Second Quarter 2024

Magle Group's Q2 report highlights organic sales growth and future market expansion with startegic mergers

MFN • 18 Jul 2024 08:30

Magle Group offentliggör fusionsdokument avseende fusionen med Amniotics

Idag meddelar Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") att fusionsdokumentet avseende fusionen ("Fusionen") med Amniotics ...

MFN • 01 Jul 2024 17:30

Förvärvet av aktierna i pK Biotech ApS och pK Chemicals A/S har genomförts

Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") har idag tillträtt aktierna i förvärvet av pK Biotech ApS ("pK Biotech") och dess...

MFN • 01 Jul 2024 14:00

Magle Group ingår samgåendeavtal avseende förvärvet av pK Biotech ApS och pK Chemicals A/S

Magle Chemoswed Holding AB ("Magle Group" eller "Bolaget") har ingått ett samgåendeavtal med PRS1 ApS (”Säljaren”) avseende förvärv av samtl...

MFN • 28 Jun 2024 08:45

BioStock: Magle Group tar hand om helheten inom CDMO

Flexibiliteten hos ett mindre företag och bredden hos de största bolagen – så beskriver Magle Group sitt erbjudande.

Cision • 20 Jun 2024 08:15

BioStock: Magle Group visar framfötterna

Magle Group fokuserar på fortsatt tillväxt genom breddning av CDMO-erbjudandet och utveckling av fler medicinska produkter baserade på Degra...

Cision • 19 Jun 2024 09:17

Magle Group offentliggör förvärv av pK Biotech ApS och pK Chemicals A/S

Magle Chemoswed Holding AB ("Magle Group") har ingått ett bindande avtal att förvärva samtliga aktier i pK Biotech ApS och dess dotterbolag ...

MFN • 17 Jun 2024 08:00

Magle Group och Amniotics går samman och skapar en ledande aktör inom högkvalitativa, livsförändrande hälsoinnovationer med ett breddat CDMO-erbjudande

Magle Chemoswed Holding AB ("Magle Group") och Amniotics AB (publ) ("Amniotics") (tillsammans "Bolagen") meddelar idag, den 30 maj 2024, att...

MFN • 30 May 2024 20:00

Magle Group fullföljer inte det offentliga uppköpserbjudandet till aktieägarna i Amniotics

Den 22 mars 2024 offentliggjorde Magle Chemoswed Holding AB ("Magle" eller "Magle Group") (STO: MAGLE), ett ledande CDMO-företag (Contract D...

MFN • 20 May 2024 23:30

MAGLE GROUP REDOVISAR UTFALL OCH FÖRLÄNGER ACCEPTPERIODEN FÖR DET OFFENTLIGA UPPKÖPSERBJUDANDET TILL AKTIEÄGARNA I AMNIOTICS

Den 22 mars 2024 offentliggjorde Magle Chemoswed Holding AB ("Magle" eller "Magle Group") (STO: MAGLE), ett ledande CDMO-företag (Contract D...

MFN • 07 May 2024 16:50

Kommuniké från årsstämma i Magle Chemoswed Holding AB (publ) den 25 april 2024

Idag, den 25 april 2024, hölls årsstämma i Magle Chemoswed Holding AB (publ).

MFN • 25 Apr 2024 13:30

Magle Chemoswed Holding Reports Financial Results For First Quarter 2024

Today, on 18 April 2024, Magle Chemoswed Holding AB (publ) has published its interim report for Q1, 2024.

MFN • 18 Apr 2024 08:30

Magle Chemoswed Holding AB offentliggör erbjudandehandling och meddelar uppdaterad tidplan avseende kontanterbjudandet till aktieägarna i Amniotics AB

Den 22 mars 2024 offentliggjorde Magle Chemoswed Holding AB ("Magle Group") ett rekommenderat offentligt uppköpserbjudande till aktieägarna ...

MFN • 05 Apr 2024 08:30

Magle Chemoswed Holding AB (publ) Releases Annual Report for 2023.

Magle Chemoswed Holding's Annual Report for 2023 has been published on the Group’s website as of today.

MFN • 26 Mar 2024 08:30

KALLELSE TILL ÅRSSTÄMMA I MAGLE CHEMOSWED HOLDING AB (PUBL)

Aktieägarna i Magle Chemoswed Holding AB (publ), org.

MFN • 25 Mar 2024 09:00

Magle Chemoswed Holding AB (publ) withdraws dividend proposal and enters into term loan facilities amounting to SEK 12 million in total

The Board of Directors' of Magle Chemoswed Holding AB (publ) (“Magle Group” or the “Company”) assessment of the Company's dividend capacity ...

MFN • 22 Mar 2024 14:00

Magle Chemoswed Holding AB lämnar ett rekommenderat kontanterbjudande om 0,004 kronor per aktie till aktieägarna i Amniotics AB

Magle Chemoswed Holding AB[1] ("Magle" eller "Magle Group") offentliggör härmed ett rekommenderat offentligt uppköpserbjudande till aktieäga...

MFN • 22 Mar 2024 07:30

Magle Chemoswed Holding AB (PUBL) – Publishes Full Year Report 2023 and Board’s Initial Proposal for Paying Dividends

Magle Chemoswed Holding AB (publ), an established innovation-led healthcare group with proven growth through risk diversification and focus ...

MFN • 16 Feb 2024 08:30

Magle Chemoswed Holding Reports Financial Results For Third Quarter 2023

Today, on 25 October 2023, Magle Chemoswed Holding AB (publ) has published its interim report for Q3 2023.

MFN • 25 Oct 2023 08:30

Magle Group enters collaboration with Sirtex Medical to support the international commercialization of EmboCept® S DSM 50 µm

Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces the establishment of a collaboration and exclusive worldwide...

MFN • 08 Sep 2023 16:05

Magle Chemoswed Holding Reports Financial Results For Second Quarter 2023

Today, on 18 Julyl 2023, Magle Chemoswed Holding AB (publ) has published its interim report for Q2 2023.

MFN • 18 Jul 2023 08:30

Magle Group applies for extended patent protection of its DSM technology in Europe

Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the company has filed a new patent application for its ...

MFN • 24 May 2023 14:30

Magle Group’s CEO purchases shares from board member

Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the company’s CEO Justin Pierace purhases 172,800 Magle...

MFN • 27 Apr 2023 17:00

Positive results from post-market clinical follow-up of Magle Group’s innovative medical device SmartPAN® presented at scientific congress

Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces the presentation of data from the company’s first post-marke...

MFN • 27 Apr 2023 08:30

Kommuniké från årsstämma i Magle Chemoswed Holding AB (publ) den 26 april 2023

Idag, den 26 april 2023, hölls årsstämma i Magle Chemoswed Holding AB (publ).

MFN • 26 Apr 2023 13:30

Magle Chemoswed Holding Reports Financial Results For First Quarter 2023

Today, on 19 April 2023, Magle Chemoswed Holding AB (publ) has published its interim report for Q1 2023.

MFN • 19 Apr 2023 08:30

Magle Chemoswed Holding AB (publ) Releases Annual Report for 2022.

Magle Chemoswed Holding's Annual Report for 2022 has been published on the Group’s website as of today.

MFN • 29 Mar 2023 15:55

KALLELSE TILL ÅRSSTÄMMA I MAGLE CHEMOSWED HOLDING AB (PUBL)

Aktieägarna i Magle Chemoswed Holding AB (publ), org nr.

MFN • 24 Mar 2023 10:00

Magle Chemsowed Holding AB (PUBL) – PUBLISHES FULL YEAR REPORT 2022

Magle Chemoswed Holding AB (publ), an established innovation led healthcare group with proven growth through risk diversification and focus ...

MFN • 16 Feb 2023 08:00

Magle Group’s proprietary product AXXO® Woundgel receives regulatory approval in Kuwait

Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that AXXO® Woundgel has received regulatory approval in Kuwa...

MFN • 21 Nov 2022 09:30

Magle Group’s vascular embolic product Embocept® S receives regulatory approval in Argentina

Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that Embocept® S has received regulatory approval in Argenti...

MFN • 17 Nov 2022 12:30

Magle Chemoswed Holding Reports Financial Results For Third Quarter 2022

Today, on 9 November 2022, Magle Chemoswed Holding AB (publ) has published its interim report for Q3 2022.

MFN • 09 Nov 2022 08:29

Invitation to presentation of Magle Group’s report for Q3 2022

Magle Chemoswed Holding AB (publ) will publish its interim report for Q3 2022 on Wednesday 9 November 2022 at 08:30 CET.

MFN • 02 Nov 2022 16:30

Magle Chemoswed Holding AB announces change of Certified Adviser to Vator Securities

Magle Chemoswed Holding AB (publ) hereby announces that the company has entered into an agreement with Vator Securities AB (“Vator Securitie...

MFN • 04 Oct 2022 16:30

Magle Group appoints new Chief Marketing and Innovation Officer

Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces the appointment of Helena Ossmer Thedius as Chief Marketing ...

MFN • 12 Sep 2022 08:50

Magle Chemoswed Holding Reports Financial Results For First Half year 2022

Magle Chemoswed Holding Reports Financial Results For First Half year 2022

MFN • 17 Aug 2022 08:00

Magle Chemoswed Holding AB announces the resignation of Julia Kamber Rouhi from the Board of Directors of Magle Chemoswed Holding.

Julia Kamber Rouhi, a deputy member of the Board of Directors of Magle Chemoswed Holding AB (publ) has announced her resignation from the Bo...

MFN • 16 Aug 2022 16:50

Invitation to presentation of Magle Chemoswed’s report for Q2 2022

Magle Chemoswed Holding AB (publ) will publish its interim report for Q2 2022 on Wednesday 17 August 2022 at 08:30 CET.

MFN • 11 Aug 2022 12:43

First patients enrolled in a post-market study of Magle Group’s innovative medical device SmartPAN®

Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today announces that the first patients have been included in a post-market ...

MFN • 11 Jul 2022 13:00

Magle Group announces innovation sponsorship with leading life science incubator in Sweden

The Magle Group’s sponsorship of the SmiLe incubator is part of the Group’s commitment to supporting early-stage companies develop and comme...

MFN • 18 May 2022 09:00

Kommuniké från årsstämma i Magle Chemoswed Holding AB (publ) den 17 Maj 2022

Kommuniké från årsstämma i Magle Chemoswed Holding AB (publ) den 17 Maj 2022

MFN • 17 May 2022 13:00

Magle Group announces post market clinical study for SmartPAN®

The Magle Group today announces that it will commence its post market clinical study in collaboration with the University of Heidelberg, Med...

MFN • 13 May 2022 08:00

Magle Group signs pre-agreement to acquire land in Malmö

The Magle Group’s presence in Malmö is further strengthened by the signing of a pre-agreement to acquire land with the City of Malmö

MFN • 09 May 2022 16:30

Invitation to presentation of Magle Chemoswed’s report for Q1 2022

Invitation to presentation of Magle Chemoswed’s report for Q1 2022

MFN • 05 May 2022 09:30

Magle Chemoswed Holding Reports Financial Results For First Quarter 2022

Magle Chemoswed Holding today reported financial results for the first quarter ended March 31, 2022, with solid profit growth year on year.

MFN • 05 May 2022 08:30

Magle Chemoswed Holding AB (publ) Releases Annual Report for 2021

Magle Chemoswed Holding's Annual Report for 2021 has been published on the Group’s website as of today

MFN • 14 Apr 2022 11:00

KALLELSE TILL ÅRSSTÄMMA I MAGLE CHEMOSWED HOLDING AB (PUBL)

Aktieägarna i Magle Chemoswed Holding AB (publ) kallas till årsstämma tisdagen den 17 maj 2022.

MFN • 13 Apr 2022 15:45

Magle Chemoswed Holding AB (publ) appoints liquidity provider

Magle Chemoswed Holding AB enters into an agreement to appoint a liquidity provider to support the trading in the shares.

MFN • 14 Mar 2022 15:30

Magle Chemsowed Holding AB (PUBL) – PUBLISHES FULL YEAR REPORT 2021

Magle Chemoswed Holding AB (publ), an established innovation led healthcare group with proven growth through risk diversification and focus ...

MFN • 25 Feb 2022 08:29

Invitation to presentation of Magle Chemoswed’s full-year report for 2021

Magle Chemoswed Holding AB (publ) will publish its full-year report for 2021 on Friday 25 February 2022 at 08:30 CET.

MFN • 22 Feb 2022 08:00

Kommuniké från extra bolagsstämma den 14 december 2021 i Magle Chemoswed Holding AB (publ)

Vid extra bolagsstämma i Magle Chemoswed Holding AB (publ) den 14 december 2021 som hölls genom poströstningsförfarande fattades i huvudsak ...

MFN • 14 Dec 2021 10:45

KALLELSE TILL EXTRA BOLAGSSTÄMMA I MAGLE CHEMOSWED HOLDING AB (PUBL)

Aktieägarna i Magle Chemoswed Holding AB (publ) kallas till extra bolagsstämma tisdagen den 14 december 2021.

MFN • 22 Nov 2021 08:30

Magle Chemoswed Holding AB announces the resignation of Hedvig Lidgard Ström from the Board of Directors of Magle Chemoswed Holding.

Hedvig Lidgard Ström, a member of the Board of Directors of Magle Chemoswed Holding AB (publ) has announced her resignation from the Board o...

MFN • 22 Nov 2021 08:00

Magle Chemoswed Holding Reports Financial Results For Third Quarter 2021

Magle Chemoswed Holding today reported financial results for the third quarter ended September 30, 2021, which are in line with expectations...

MFN • 16 Nov 2021 08:30

Magle Chemoswed appoints new Chief Strategy Officer

Magle Chemoswed Holding is pleased to announce the appointment of Simon Jegou as Chief Strategy Officer of the Magle Chemoswed Holding Group...

MFN • 16 Nov 2021 08:00

Invitation to presentation of Magle Chemoswed’s report for Q3 2021

Magle Chemoswed Holding AB (publ) will publish its quarterly report for Q3 2021 on Tuesday 16 November 2021 at 08:30 CET.

MFN • 09 Nov 2021 14:05

EmboCept®S included in the European treatment guidelines

EmboCept® S is included in leading European guidelines for recommended therapeutic use

MFN • 29 Oct 2021 09:30

Magle Chemoswed establishes a manufacturing agreement with Oncopeptides

Magle Chemoswed establishes a manufacturing agreement with Oncopeptides

MFN • 15 Sep 2021 13:50

Magle Chemoswed announces confirmation of manufacturing order for delivery in 2022.

Magle Chemoswed announces confirmation of a large order of Isradipine for a new customer for delivery in the second quarter of 2022.

MFN • 01 Sep 2021 08:58

Västra Hamnen: Magle Chemoswed - Looking up

Västra Hamnen Corporate Finance has released a research update on Magle Chemoswed following the company's report for Q2 2021.

Cision • 18 Aug 2021 16:22

Magle Chemoswed Holding AB today announced financial results for the second quarter of 2021

The second quarter of 2021 is in line with forecast with strong demand in the CDMO services and manufacturing.

MFN • 17 Aug 2021 07:00

Invitation to presentation of Magle Chemoswed’s report for Q2 2021

Magle Chemoswed Holding AB (publ) will publish its quarterly report for Q2 2021 on Tuesday 17 August 2021 at 08:30 CET.

MFN • 13 Aug 2021 12:50

Magle Chemoswed Holding (publ) today announced that it has filed a patent application that will be used in the ongoing SmartBONE project in the field of bone tissue engineering.

The addition of the patent application extends the protection of Magle Chemoswed’s technology platform and strengthens the future market pro...

MFN • 20 Jul 2021 13:40